Hemenway Trust Co LLC Buys 5,696 Shares of Johnson & Johnson (NYSE:JNJ)

Hemenway Trust Co LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 206,245 shares of the company's stock after purchasing an additional 5,696 shares during the period. Johnson & Johnson accounts for about 2.8% of Hemenway Trust Co LLC's holdings, making the stock its 17th biggest position. Hemenway Trust Co LLC's holdings in Johnson & Johnson were worth $34,204,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Planning Center Inc. increased its holdings in Johnson & Johnson by 11.9% during the first quarter. Planning Center Inc. now owns 2,574 shares of the company's stock worth $427,000 after buying an additional 273 shares during the last quarter. GSB Wealth Management LLC raised its position in shares of Johnson & Johnson by 0.7% in the first quarter. GSB Wealth Management LLC now owns 30,795 shares of the company's stock valued at $5,107,000 after purchasing an additional 213 shares during the period. Optivise Advisory Services LLC boosted its holdings in Johnson & Johnson by 8.1% in the 1st quarter. Optivise Advisory Services LLC now owns 2,265 shares of the company's stock worth $376,000 after buying an additional 169 shares during the period. Tennessee Valley Asset Management Partners grew its stake in Johnson & Johnson by 19.7% in the 1st quarter. Tennessee Valley Asset Management Partners now owns 3,118 shares of the company's stock valued at $517,000 after buying an additional 514 shares in the last quarter. Finally, PKO Investment Management Joint Stock Co raised its holdings in Johnson & Johnson by 2.1% during the 1st quarter. PKO Investment Management Joint Stock Co now owns 24,500 shares of the company's stock valued at $4,063,000 after acquiring an additional 500 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Bank of America lowered their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Morgan Stanley upped their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Finally, Barclays decreased their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Trading Down 1.1%

JNJ traded down $1.61 during trading on Thursday, hitting $150.77. 8,323,506 shares of the stock traded hands, compared to its average volume of 7,967,133. The firm has a market capitalization of $362.76 billion, a P/E ratio of 16.77, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The firm has a 50-day moving average of $154.06 and a 200 day moving average of $153.67. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.45%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.